363 related articles for article (PubMed ID: 35017721)
1. Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine.
Dutta AK; Alberge JB; Sklavenitis-Pistofidis R; Lightbody ED; Getz G; Ghobrial IM
Nat Rev Clin Oncol; 2022 Apr; 19(4):223-236. PubMed ID: 35017721
[TBL] [Abstract][Full Text] [Related]
2. Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability.
Dutta AK; Fink JL; Grady JP; Morgan GJ; Mullighan CG; To LB; Hewett DR; Zannettino ACW
Leukemia; 2019 Feb; 33(2):457-468. PubMed ID: 30046162
[TBL] [Abstract][Full Text] [Related]
3. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
Manier S; Kawano Y; Bianchi G; Roccaro AM; Ghobrial IM
Curr Opin Hematol; 2016 Jul; 23(4):426-33. PubMed ID: 27101529
[TBL] [Abstract][Full Text] [Related]
4. From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells.
van Nieuwenhuijzen N; Spaan I; Raymakers R; Peperzak V
Cancer Res; 2018 May; 78(10):2449-2456. PubMed ID: 29703720
[TBL] [Abstract][Full Text] [Related]
5. Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma.
Tomasson MH; Ali M; De Oliveira V; Xiao Q; Jethava Y; Zhan F; Fitzsimmons AM; Bates ML
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30453544
[TBL] [Abstract][Full Text] [Related]
6. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.
Cowan A; Ferrari F; Freeman SS; Redd R; El-Khoury H; Perry J; Patel V; Kaur P; Barr H; Lee DJ; Lightbody E; Downey K; Argyelan D; Theodorakakou F; Fotiou D; Liacos CI; Kanellias N; Chavda SJ; Ainley L; Sandecká V; Pospíšilová L; Minarik J; Jungova A; Radocha J; Spicka I; Nadeem O; Yong K; Hájek R; Kastritis E; Marinac CR; Dimopoulos MA; Get G; Trippa L; Ghobrial IM
Lancet Haematol; 2023 Mar; 10(3):e203-e212. PubMed ID: 36858677
[TBL] [Abstract][Full Text] [Related]
7. Prevention of progression in monoclonal gammopathy of undetermined significance.
Rajkumar SV
Clin Cancer Res; 2009 Sep; 15(18):5606-8. PubMed ID: 19737944
[TBL] [Abstract][Full Text] [Related]
8. Towards Stratified Medicine in Plasma Cell Myeloma.
Egan P; Drain S; Conway C; Bjourson AJ; Alexander HD
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775669
[TBL] [Abstract][Full Text] [Related]
9. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
Mikulasova A; Wardell CP; Murison A; Boyle EM; Jackson GH; Smetana J; Kufova Z; Pour L; Sandecka V; Almasi M; Vsianska P; Gregora E; Kuglik P; Hajek R; Davies FE; Morgan GJ; Walker BA
Haematologica; 2017 Sep; 102(9):1617-1625. PubMed ID: 28550183
[TBL] [Abstract][Full Text] [Related]
10. Multiple myeloma.
van de Donk NWCJ; Pawlyn C; Yong KL
Lancet; 2021 Jan; 397(10272):410-427. PubMed ID: 33516340
[TBL] [Abstract][Full Text] [Related]
11. [Pathogenesis of multiple myeloma].
Rasche L; Weinhold N
Internist (Berl); 2019 Jan; 60(1):3-9. PubMed ID: 30536029
[TBL] [Abstract][Full Text] [Related]
12. The bone-marrow niche in MDS and MGUS: implications for AML and MM.
Ghobrial IM; Detappe A; Anderson KC; Steensma DP
Nat Rev Clin Oncol; 2018 Apr; 15(4):219-233. PubMed ID: 29311715
[TBL] [Abstract][Full Text] [Related]
13. A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics.
Awada H; Thapa B; Awada H; Dong J; Gurnari C; Hari P; Dhakal B
Cells; 2021 Aug; 10(8):. PubMed ID: 34440730
[TBL] [Abstract][Full Text] [Related]
14. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease.
Dang M; Wang R; Lee HC; Patel KK; Becnel MR; Han G; Thomas SK; Hao D; Chu Y; Weber DM; Lin P; Lutter-Berka Z; Berrios Nolasco DA; Huang M; Bansal H; Song X; Zhang J; Futreal A; Moreno Rueda LY; Symer DE; Green MR; Rojas Hernandez CM; Kroll M; Afshar-Khargan V; Ndacayisaba LJ; Kuhn P; Neelapu SS; Orlowski RZ; Wang L; Manasanch EE
Cancer Cell; 2023 Jun; 41(6):1032-1047.e4. PubMed ID: 37311413
[TBL] [Abstract][Full Text] [Related]
15. Multiple myeloma in the marrow: pathogenesis and treatments.
Fairfield H; Falank C; Avery L; Reagan MR
Ann N Y Acad Sci; 2016 Jan; 1364(1):32-51. PubMed ID: 27002787
[TBL] [Abstract][Full Text] [Related]
16. Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions.
Chojnacka M; Diamond B; Landgren O; Maura F
Semin Oncol; 2022 Feb; 49(1):11-18. PubMed ID: 35168813
[TBL] [Abstract][Full Text] [Related]
17. Multiple myeloma: current perspectives.
Slovak ML
Clin Lab Med; 2011 Dec; 31(4):699-724, x. PubMed ID: 22118745
[TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma and multiple plasmacytomas associated with free gamma heavy chain, free kappa light chain and IgGk paraproteins: an unusual triple gammopathy.
Deighan WI; O'Kane MJ; McNicholl FP; Keren DF
Ann Clin Biochem; 2016 Nov; 53(6):706-711. PubMed ID: 27166317
[TBL] [Abstract][Full Text] [Related]
19. Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.
Mailankody S; Mena E; Yuan CM; Balakumaran A; Kuehl WM; Landgren O
Leuk Lymphoma; 2010 Dec; 51(12):2159-70. PubMed ID: 20958231
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells.
Schmidt-Hieber M; Gutiérrez ML; Pérez-Andrés M; Paiva B; Rasillo A; Tabernero MD; Sayagués JM; Lopez A; Bárcena P; Sanchez ML; Gutiérrez NC; San Miguel JF; Orfao A
Haematologica; 2013 Feb; 98(2):279-87. PubMed ID: 22929983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
